

# Björn Meijers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3758286/publications.pdf>

Version: 2024-02-01

273  
papers

17,425  
citations

10389

72  
h-index

17105

122  
g-index

277  
all docs

277  
docs citations

277  
times ranked

13608  
citing authors

#	ARTICLE	IF	CITATIONS
1	Heterologous versus homologous triple anti-COVID-19 vaccine regimens in patients on maintenance haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, 1384-1386.	0.7	7
2	Effects of an SGLT Inhibitor on the Production, Toxicity, and Elimination of Gut-Derived Uremic Toxins: A Call for Additional Evidence. <i>Toxins</i> , 2022, 14, 210.	3.4	5
3	The Evolving View of Uremic Toxicity. <i>Toxins</i> , 2022, 14, 274.	3.4	3
4	Incidence, Characteristics, and Outcome of COVID-19 in Adults on Kidney Replacement Therapy: A Regionwide Registry Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 385-396.	6.1	101
5	Patterns of renal osteodystrophy 1â€™%year after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2130-2139.	0.7	11
6	Life-threatening paraneoplastic cardiovascular events in ALK-positive anaplastic large cell lymphoma. <i>Annals of Hematology</i> , 2021, 100, 2851-2853.	1.8	1
7	Apixaban in patients on haemodialysis: a single-dose pharmacokinetics study. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 884-889.	0.7	7
8	Strategies for asymmetrical triacetate dialyser heparin-free effective haemodialysis: the SAFE study. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1901-1907.	2.9	10
9	The clinical characteristics of coronavirus-associated nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1279-1281.	0.7	14
10	Sevelamer Use in End-Stage Kidney Disease (ESKD) Patients Associates with Poor Vitamin K Status and High Levels of Gut-Derived Uremic Toxins: A Drugâ€™Bug Interaction?. <i>Toxins</i> , 2020, 12, 351.	3.4	14
11	The association between use of proton-pump inhibitors and excess mortality after kidney transplantation: A cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003140.	8.4	9
12	Comparison of 2 Serum-Free Light-Chain Assays in CKD Patients. <i>Kidney International Reports</i> , 2020, 5, 627-631.	0.8	13
13	The Role of Gut Dysbiosis in the Boneâ€™Vascular Axis in Chronic Kidney Disease. <i>Toxins</i> , 2020, 12, 285.	3.4	23
14	A distinct bone phenotype in ADPKD patients with end-stage renal disease. <i>Kidney International</i> , 2019, 95, 412-419.	5.2	23
15	Clinical Inference of Serum and Bone Sclerostin Levels in Patients with End-Stage Kidney Disease. <i>Journal of Clinical Medicine</i> , 2019, 8, 2027.	2.4	15
16	Linking gut microbiota to cardiovascular disease and hypertension: Lessons from chronic kidney disease. <i>Pharmacological Research</i> , 2018, 133, 101-107.	7.1	38
17	Sclerostin and chronic kidney disease: the assay impacts what we (thought to) know. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1404-1410.	0.7	22
18	Bone and mineral disorders in chronic kidney disease: implications for cardiovascular health and ageing in the general population. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 319-331.	11.4	102

#	ARTICLE	IF	CITATIONS
19	Sclerostin deficiency modifies the development of CKD-MBD in mice. <i>Bone</i> , 2018, 107, 115-123.	2.9	20
20	Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease—Mineral and Bone Disorder: Synopsis of the Kidney Disease: Improving Global Outcomes 2017 Clinical Practice Guideline Update. <i>Annals of Internal Medicine</i> , 2018, 168, 422.	3.9	228
21	Synthesis and post-functionalization of alternate-linked-meta-para-[2 n .1 n ]thiacyclophanes. <i>Beilstein Journal of Organic Chemistry</i> , 2018, 14, 2190-2197.	2.2	3
22	Nephrotic Syndrome: Genetics, Mechanism, and Therapies. <i>BioMed Research International</i> , 2018, 2018, 1-2.	1.9	10
23	Intestinal Barrier Function in Chronic Kidney Disease. <i>Toxins</i> , 2018, 10, 298.	3.4	78
24	Clinical case report: a rare cause of acute kidney failure — tissue is the issue. <i>Acta Clinica Belgica</i> , 2017, 72, 201-204.	1.2	3
25	Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial. <i>BMC Nephrology</i> , 2017, 18, 24.	1.8	13
26	Sclerostin—A Debutant on the Autosomal Dominant Polycystic Kidney Disease Scene?. <i>Kidney International Reports</i> , 2017, 2, 481-485.	0.8	6
27	1 $\alpha$ ,25-Dihydroxyvitamin D 3 : A new vitamin D metabolite in human serum. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2017, 173, 341-348.	2.5	18
28	Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative—a position paper. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1608-1613.	0.7	41
29	Biomarkers Predicting Bone Turnover in the Setting of CKD. <i>Current Osteoporosis Reports</i> , 2017, 15, 178-186.	3.6	34
30	A noninferiority trial comparing a heparin-grafted membrane plus citrate-containing dialysate versus regional citrate anticoagulation: results of the CITED study. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 707-714.	0.7	20
31	Circulating markers of bone turnover. <i>Journal of Nephrology</i> , 2017, 30, 663-670.	2.0	53
32	Executive summary of the 2017 KDIGO Chronic Kidney Disease—Mineral and Bone Disorder (CKD-MBD) Guideline Update: what's changed and why it matters. <i>Kidney International</i> , 2017, 92, 26-36.	5.2	698
33	Exploring binding characteristics and the related competition of different protein-bound uremic toxins. <i>Biochimie</i> , 2017, 139, 20-26.	2.6	19
34	Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, 1530-1539.	0.7	38
35	Ligand trap for the activin type IIA receptor. The long-sought drug to overcome the calcification paradox in CKD?. <i>Kidney International</i> , 2017, 91, 11-13.	5.2	4
36	Bone histomorphometry in de novo renal transplant recipients indicates a further decline in bone resorption 1 year posttransplantation. <i>Kidney International</i> , 2017, 91, 469-476.	5.2	40

#	ARTICLE	IF	CITATIONS
37	Evidence for Bone and Mineral Metabolism Alterations in Children With Autosomal Dominant Polycystic Kidney Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 4210-4217.	3.6	15
38	Update on the role of bone biopsy in the management of patients with CKD-MBD. <i>Journal of Nephrology</i> , 2017, 30, 645-652.	2.0	31
39	p-cresol sulfate and indoxyl sulfate: some clouds are gathering in the uremic toxin sky. <i>Kidney International</i> , 2017, 92, 1323-1324.	5.2	22
40	The gut-kidney axis. <i>Pediatric Nephrology</i> , 2017, 32, 2005-2014.	1.7	188
41	Recent Progress in Deciphering the Etiopathogenesis of Primary Membranous Nephropathy. <i>BioMed Research International</i> , 2017, 2017, 1-14.	1.9	11
42	Circulating levels of sclerostin but not DKK1 associate with laboratory parameters of CKD-MBD. <i>PLoS ONE</i> , 2017, 12, e0176411.	2.5	37
43	The Influence of Prebiotic Arabinoxylan Oligosaccharides on Microbiota Derived Uremic Retention Solutes in Patients with Chronic Kidney Disease: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2016, 11, e0153893.	2.5	74
44	Immunologic Changes Implicated in the Pathogenesis of Focal Segmental Glomerulosclerosis. <i>BioMed Research International</i> , 2016, 2016, 1-5.	1.9	19
45	Two Cases of Heavy Chain MGUS. <i>Case Reports in Oncological Medicine</i> , 2016, 2016, 1-4.	0.3	4
46	FSGS: Diagnosis and Diagnostic Work-Up. <i>BioMed Research International</i> , 2016, 2016, 1-8.	1.9	26
47	Oxidative Stress in Chronic Kidney Disease. <i>Oxidative Medicine and Cellular Longevity</i> , 2016, 2016, 1-2.	4.0	30
48	Focal Segmental Glomerulosclerosis: Genetics, Mechanism, and Therapies. <i>BioMed Research International</i> , 2016, 2016, 1-2.	1.9	3
49	Soluble Urokinase Receptors in Focal Segmental Glomerulosclerosis: A Review on the Scientific Point of View. <i>Journal of Immunology Research</i> , 2016, 2016, 1-14.	2.2	45
50	The acute kidney injury e-alert and clinical care bundles: the road to success is always under construction. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1761-1763.	0.7	4
51	A liquid chromatography tandem mass spectrometry method to measure a selected panel of uremic retention solutes derived from endogenous and colonic microbial metabolism. <i>Analytica Chimica Acta</i> , 2016, 936, 149-156.	5.4	40
52	Magnesium-based interventions for normal kidney function and chronic kidney disease. <i>Magnesium Research</i> , 2016, 29, 126-140.	0.5	18
53	Decreased Circulating Sclerostin Levels in Renal Transplant Recipients With Persistent Hyperparathyroidism. <i>Transplantation</i> , 2016, 100, 2188-2193.	1.0	21
54	Vitamin K Dependent Protection of Renal Function in Multi-ethnic Population Studies. <i>EBioMedicine</i> , 2016, 4, 162-169.	6.1	44

#	ARTICLE	IF	CITATIONS
55	Microbiota-Derived Phenylacetylglutamine Associates with Overall Mortality and Cardiovascular Disease in Patients with CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3479-3487.	6.1	144
56	Metabolism, Protein Binding, and Renal Clearance of Microbiota-Derived p-Cresol in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1136-1144.	4.5	57
57	Effect of Treatment Duration and Frequency on Uremic Solute Kinetics, Clearances and Concentrations. <i>Seminars in Dialysis</i> , 2016, 29, 463-470.	1.3	4
58	Mineral metabolism disturbances in kidney donors: smoke, no fire (yet). <i>Kidney International</i> , 2016, 90, 734-736.	5.2	1
59	Parathyroid hormone metabolism and signaling in health and chronic kidney disease. <i>Kidney International</i> , 2016, 90, 1184-1190.	5.2	123
60	[OP.1B.01] VITAMIN K DEPENDENT PROTECTION OF RENAL FUNCTION IN MULTI-ETHNIC POPULATION STUDIES. <i>Journal of Hypertension</i> , 2016, 34, e5.	0.5	0
61	Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid. <i>Transplantation</i> , 2016, 100, e50-e51.	1.0	8
62	HEMO Revisited: Why Kt/Vurea Only Tells Part of the Story. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 3235-3237.	6.1	11
63	Adverse Effects of Proton Pump Inhibitors in Chronic Kidney Disease. <i>JAMA Internal Medicine</i> , 2016, 176, 866.	5.1	6
64	The Case   Hypercalcemia in a child with chronic kidney disease. <i>Kidney International</i> , 2016, 90, 233-234.	5.2	2
65	Dietary phosphorus restriction in predialysis chronic kidney disease: time for a cease-fire?. <i>Kidney International</i> , 2016, 89, 21-23.	5.2	7
66	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1211-1219.	0.7	52
67	Phosphorus metabolism in peritoneal dialysis- and haemodialysis-treated patients. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1508-1514.	0.7	32
68	The influence of renal transplantation on retained microbial-human co-metabolites. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1721-1729.	0.7	35
69	Inflammation and the bone-vascular axis in end-stage renal disease. <i>Osteoporosis International</i> , 2016, 27, 489-497.	3.1	33
70	Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target. <i>American Journal of Kidney Diseases</i> , 2016, 67, 483-498.	1.9	271
71	The Influence of CKD on Colonic Microbial Metabolism. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1389-1399.	6.1	106
72	Proteinuria as a Noninvasive Marker for Renal Allograft Histology and Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 281-292.	6.1	65

#	ARTICLE	IF	CITATIONS
73	From skeletal to cardiovascular disease in 12 stepsâ€”the evolution of sclerostin as a major player in CKD-MBD. <i>Pediatric Nephrology</i> , 2016, 31, 195-206.	1.7	51
74	The Effect of Anastomosis Time on Outcome in Recipients of Kidneys Donated After Brain Death: A Cohort Study. <i>American Journal of Transplantation</i> , 2015, 15, 2900-2907.	4.7	43
75	Reassessing the Reassessment of suPAR in Glomerular Disease. <i>Frontiers in Medicine</i> , 2015, 1, 59.	2.6	5
76	FP594TARGETING MICROBIOTA DERIVED UREMIC RETENTION SOLUTES WITH ANTIBIOTICS. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii271-iii271.	0.7	0
77	SP691THE SOLUBLE UROKINASE RECEPTOR (SUPAR) PREDICTS MORTALITY IN END-STAGE RENAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, iii607-iii607.	0.7	0
78	Microscopic nephrocalcinosis in chronic kidney disease patients. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 843-848.	0.7	17
79	The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 791-799.	4.5	75
80	Percutaneous Rheolytic Thrombectomy of Thrombosed Autogenous Dialysis Fistulas. <i>Journal of Endovascular Therapy</i> , 2015, 22, 80-86.	1.5	27
81	Blueprint for a European calciphylaxis registry initiative: the European Calciphylaxis Network (EuCalNet). <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 567-571.	2.9	12
82	The fate of triaged and rejected manuscripts. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1947-1950.	0.7	9
83	Invasive Aspergillosis After Kidney Transplant: Case-Control Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1505-1511.	5.8	38
84	Pro: Cardiovascular calcifications are clinically relevant. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 345-351.	0.7	53
85	Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis. <i>Circulation</i> , 2015, 132, 27-39.	1.6	259
86	Sclerostin and DKK1: new players in renal bone and vascular disease. <i>Kidney International</i> , 2015, 88, 235-240.	5.2	118
87	The metabolomics grail: promising although not yet holy. <i>Kidney International</i> , 2015, 87, 864.	5.2	1
88	Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 698-700.	0.7	23
89	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 357-357.	0.7	6
90	Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4669-4676.	3.6	53

#	ARTICLE	IF	CITATIONS
91	Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. <i>Kidney International</i> , 2015, 87, 210-216.	5.2	52
92	Associations of Soluble CD14 and Endotoxin with Mortality, Cardiovascular Disease, and Progression of Kidney Disease among Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1525-1533.	4.5	59
93	High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 288-293.	0.7	111
94	The Influence of Dietary Protein Intake on Mammalian Tryptophan and Phenolic Metabolites. <i>PLoS ONE</i> , 2015, 10, e0140820.	2.5	77
95	Heritability and Clinical Determinants of Serum Indoxyl Sulfate and p-Cresyl Sulfate, Candidate Biomarkers of the Human Microbiome Enterotype. <i>PLoS ONE</i> , 2014, 9, e79682.	2.5	28
96	The Clinical Features of Trombotic Microangiopathies Post Transplantation.. <i>Transplantation</i> , 2014, 98, 532.	1.0	0
97	The Impact of Renal Transplantation On Microbiota Derived Uremic Retention Solutes.. <i>Transplantation</i> , 2014, 98, 577.	1.0	0
98	Heparin-coated dialyzer membranes: is non-inferiority good enough?. <i>Kidney International</i> , 2014, 86, 1084-1086.	5.2	18
99	The Hype Cycle for Soluble Urokinase Receptor in FSGS. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 1835-1836.	4.5	5
100	Serum Concentrations of p-Cresyl Sulfate and Indoxyl Sulfate, But Not Inflammatory Markers, Increase in Incident Peritoneal Dialysis Patients in Parallel with Loss of Residual Renal Function. <i>Peritoneal Dialysis International</i> , 2014, 34, 71-78.	2.3	34
101	Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis. <i>Kidney International</i> , 2014, 86, 1001-1006.	5.2	13
102	A Randomized Study Evaluating Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients With Persistent Hyperparathyroidism. <i>American Journal of Transplantation</i> , 2014, 14, 2545-2555.	4.7	77
103	Introduction: Mineral Bone Disorder Is a Key Player in Chronic Kidney Disease. <i>Seminars in Nephrology</i> , 2014, 34, 577.	1.6	0
104	The Histology of Kidney Transplant Failure. <i>Transplantation</i> , 2014, 98, 427-435.	1.0	124
105	The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. <i>Kidney International</i> , 2014, 85, 636-640.	5.2	106
106	Romosozumab in Postmenopausal Women with Osteopenia. <i>New England Journal of Medicine</i> , 2014, 370, 1664-1665.	27.0	66
107	Nonextracorporeal Methods for Decreasing Uremic Solute Concentration: A Future Way To Go?. <i>Seminars in Nephrology</i> , 2014, 34, 228-243.	1.6	25
108	Cardiovascular disease relates to intestinal uptake of p-cresol in patients with chronic kidney disease. <i>BMC Nephrology</i> , 2014, 15, 87.	1.8	48

#	ARTICLE	IF	CITATIONS
109	Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 1965-1972.	0.7	10
110	Laboratory Abnormalities in CKD-MBD: Markers, Predictors, or Mediators of Disease?. <i>Seminars in Nephrology</i> , 2014, 34, 151-163.	1.6	62
111	A balanced view of calcium and phosphate homeostasis in chronic kidney disease. <i>Kidney International</i> , 2013, 83, 789-791.	5.2	21
112	Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. <i>Transplant International</i> , 2013, 26, 973-981.	1.6	36
113	Albumin is the main plasma binding protein for indoxyl sulfate and p-cresyl sulfate. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 165-175.	1.9	104
114	The Colon: An Overlooked Site for Therapeutics in Dialysis Patients. <i>Seminars in Dialysis</i> , 2013, 26, 323-332.	1.3	71
115	Safety Issues Related to Fractionated Plasma Separation, Adsorption, and Dialysis. <i>Artificial Organs</i> , 2013, 37, 743-744.	1.9	0
116	Chronic Histological Damage in Early Indication Biopsies Is an Independent Risk Factor for Late Renal Allograft Failure. <i>American Journal of Transplantation</i> , 2013, 13, 86-99.	4.7	56
117	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. <i>Hepatology</i> , 2013, 57, 1153-1162.	7.3	452
118	Combined Kidney and Intestinal Transplantation in Patients With Enteric Hyperoxaluria Secondary to Short Bowel Syndrome. <i>American Journal of Transplantation</i> , 2013, 13, 1910-1914.	4.7	19
119	Renal safety in patients treated with bisphosphonates for osteoporosis: A review. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2049-2059.	2.8	91
120	Recovery Versus Persistence of Disordered Mineral Metabolism in Kidney Transplant Recipients. <i>Seminars in Nephrology</i> , 2013, 33, 191-203.	1.6	81
121	Sclerostin: Another Vascular Calcification Inhibitor?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3221-3228.	3.6	143
122	Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 3024-3030.	0.7	105
123	Intrarenal Resistive Index after Renal Transplantation. <i>New England Journal of Medicine</i> , 2013, 369, 1797-1806.	27.0	185
124	POST-STREPTOCOCCAL GLOMERULONEPHRITIS: NOT AN EXTINCT DISEASE!. <i>Acta Clinica Belgica</i> , 2013, 68, 215-217.	1.2	2
125	De novo INF2 mutations expand the genetic spectrum of hereditary neuropathy with glomerulopathy. <i>Neurology</i> , 2013, 81, 1953-1958.	1.1	35
126	Renal Clearance and Intestinal Generation of p-Cresyl Sulfate and Indoxyl Sulfate in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1508-1514.	4.5	93



#	ARTICLE	IF	CITATIONS
127	Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome. <i>Transplant International</i> , 2013, 26, 813-821.	1.6	51
128	Anticoagulation With Fondaparinux for Hemodiafiltration in Patients With Heparin-Induced Thrombocytopenia: Dose-Finding Study and Safety Evaluation. <i>Artificial Organs</i> , 2013, 37, 482-487.	1.9	21
129	suPAR and FSGS. <i>Transplantation</i> , 2013, 96, 368-369.	1.0	8
130	Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2017-2022.	0.7	36
131	Calcium balance in chronic kidney disease: walking the tightrope. <i>Kidney International</i> , 2012, 81, 1057-1059.	5.2	8
132	Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis. <i>New England Journal of Medicine</i> , 2012, 367, 2482-2494.	27.0	805
133	Effects of a wheat bran extract containing arabinoxylan oligosaccharides on gastrointestinal health parameters in healthy adult human volunteers: a double-blind, randomised, placebo-controlled, cross-over trial. <i>British Journal of Nutrition</i> , 2012, 108, 2229-2242.	2.3	106
134	Impact of Vascular Calcification on Corrected QT Interval at the Time of Renal Transplantation. <i>American Journal of Nephrology</i> , 2012, 35, 24-30.	3.1	13
135	Evidence in Favor of a Severely Impaired Net Intestinal Calcium Absorption in Patients with (Early-Stage) Chronic Kidney Disease. <i>American Journal of Nephrology</i> , 2012, 35, 434-441.	3.1	17
136	Uremia Suppresses Immune Signal-Induced CYP27B1 Expression in Human Monocytes. <i>American Journal of Nephrology</i> , 2012, 36, 497-508.	3.1	34
137	Daytime Rhythm and Treatment-Related Fluctuations of Serum Phosphorus Concentration in Dialysis Patients. <i>American Journal of Nephrology</i> , 2012, 35, 242-248.	3.1	16
138	Cardiovascular complications in CKD 5D. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, ii227-ii251.	0.7	0
139	Recipients' Smoking Habits and Death-Censored Renal Allograft Survival. <i>Transplantation</i> , 2012, 94, 24.	1.0	0
140	A prospective randomized open-label crossover trial of regional citrate anticoagulation vs. anticoagulation free liver dialysis by the Molecular Adsorbents Recirculating System. <i>Critical Care</i> , 2012, 16, R20.	5.8	38
141	Phosphate binder therapy "cracks in the tower of strength?". <i>Nature Reviews Nephrology</i> , 2012, 8, 615-616.	9.6	4
142	Dietary fiber and protein: nutritional therapy in chronic kidney disease and beyond. <i>Kidney International</i> , 2012, 81, 227-229.	5.2	41
143	Stability of Therapeutic Albumin Solutions Used for Molecular Adsorbent Recirculating System-Based Liver Dialysis. <i>Artificial Organs</i> , 2012, 36, 29-41.	1.9	9
144	Hemolytic anemia associated with severe hypophosphatemia in a renal transplant recipient. <i>Transplant International</i> , 2012, 25, e27-e28.	1.6	3

#	ARTICLE	IF	CITATIONS
145	Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. <i>Clinical Transplantation</i> , 2012, 26, 393-402.	1.6	36
146	The Many Faces of Merlin. <i>Chest</i> , 2011, 140, 791-794.	0.8	5
147	Targeting FGF23 and phosphorus in CKD, do not forget calcium. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1749-1750.	0.7	1
148	Prevalence and determinants of anemia in the immediate postkidney transplant period. <i>Transplant International</i> , 2011, 24, 1208-1215.	1.6	19
149	Reduction in Protein-Bound Solutes Unacceptable as Marker of Dialysis Efficacy during Alternate-Night Nocturnal Hemodialysis. <i>American Journal of Nephrology</i> , 2011, 34, 226-232.	3.1	22
150	The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 759-761.	0.7	203
151	Warning: the unfortunate end of p-cresol as a uraemic toxin. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1464-1467.	0.7	86
152	PTH, FGF23, and calcium: it takes three to tango?. <i>Kidney International</i> , 2011, 80, 1377.	5.2	11
153	Troponin I Is a Predictor of Acute Cardiac Events in the Immediate Postoperative Renal Transplant Period. <i>Transplantation</i> , 2010, 89, 341-346.	1.0	11
154	Maintenance Immunosuppressive Agents as Risk Factors for BK Virus Nephropathy: The Need for True Drug Exposure Measurements. <i>Transplantation</i> , 2010, 89, 1296-1297.	1.0	6
155	Authors' Reply: Troponin I and Cardiovascular Events in Transplant Patients. <i>Transplantation</i> , 2010, 90, 339-340.	1.0	0
156	Response to "Tertiary hyperparathyroidism: Is less than a subtotal resection ever appropriate? A study on long-term outcomes". <i>Surgery</i> , 2010, 148, 1044-1045.	1.9	4
157	Fibroblast Growth Factor-23 and Parathyroid Hormone Are Associated with Post-Transplant Bone Mineral Density Loss. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1887-1892.	4.5	36
158	Fibroblast Growth Factor-23 in Early Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1268-1276.	4.5	96
159	p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 219-224.	0.7	260
160	Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2672-2679.	0.7	77
161	Targeting hyperphosphatemia: truth or dare. <i>Kidney International</i> , 2010, 77, 256-257.	5.2	1
162	Measuring Total Blood Calcium Displays a Low Sensitivity for the Diagnosis of Hypercalcemia in Incident Renal Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2085-2092.	4.5	23

#	ARTICLE	IF	CITATIONS
163	p-Cresol and Cardiovascular Risk in Mild-to-Moderate Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1182-1189.	4.5	265
164	Quantification of <sup>15</sup> N-Nitrate in Urine with Gas Chromatography Combustion Isotope Ratio Mass Spectrometry to Estimate Endogenous NO Production. <i>Analytical Chemistry</i> , 2010, 82, 601-607.	6.5	10
165	Coagulation and Fractionated Plasma Separation and Adsorption. <i>American Journal of Transplantation</i> , 2009, 9, 242-243.	4.7	3
166	p-Cresyl Sulfate and Indoxyl Sulfate in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1932-1938.	4.5	142
167	Recipient-derived chronic lymphocytic leukaemia diagnosed shortly after kidney transplantation on protocol biopsy. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3886-3890.	0.7	6
168	Uremic toxins originating from colonic microbial metabolism. <i>Kidney International</i> , 2009, 76, S12-S19.	5.2	349
169	Simultaneous Control of PTH and Ca <sup>2+</sup> -P Is Sustained over Three Years of Treatment with Cinacalcet HCl. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1465-1476.	4.5	29
170	Calcium Metabolism in the Early Posttransplantation Period. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 665-672.	4.5	72
171	Localization, Etiology and Impact of Calcium Phosphate Deposits in Renal Allografts. <i>American Journal of Transplantation</i> , 2009, 9, 2470-2478.	4.7	46
172	Immunogenicity of a Standard Trivalent Influenza Vaccine in Patients on Long-term Hemodialysis: An Open-Label Trial. <i>American Journal of Kidney Diseases</i> , 2009, 54, 77-85.	1.9	63
173	The Uremic Retention Solute p-Cresyl Sulfate and Markers of Endothelial Damage. <i>American Journal of Kidney Diseases</i> , 2009, 54, 891-901.	1.9	219
174	Opinion: When is Vitamin D Contraindicated in Dialysis Patients?. <i>Seminars in Dialysis</i> , 2009, 22, 242-244.	1.3	0
175	Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography. <i>Journal of Chromatography A</i> , 2009, 1216, 4684-4688.	3.7	65
176	Removal of the Uremic Retention Solute p-Cresol Using Fractionated Plasma Separation and Adsorption. <i>Artificial Organs</i> , 2008, 32, 214-219.	1.9	60
177	A Review of Albumin Binding in CKD. <i>American Journal of Kidney Diseases</i> , 2008, 51, 839-850.	1.9	99
178	Influenza Vaccination Is Efficacious and Safe in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2008, 8, 332-337.	4.7	139
179	Calcium Requirements after Parathyroidectomy in Patients with Refractory Secondary Hyperparathyroidism. <i>Nephron Clinical Practice</i> , 2008, 110, c80-c85.	2.3	51
180	A single-centre study of adjuvant cidofovir therapy for BK virus interstitial nephritis (BKVIN) in renal allograft recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 63, 417-419.	3.0	29

#	ARTICLE	IF	CITATIONS
181	Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2033-2042.	0.7	65
182	Calcimimetics in chronic kidney disease: evidence, opportunities and challenges. <i>Kidney International</i> , 2008, 74, 265-275.	5.2	40
183	Recovery of Hyperphosphatemia and Renal Phosphorus Wasting One Year after Successful Renal Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1829-1836.	4.5	124
184	Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 278-285.	0.7	70
185	Free p-cresol is associated with cardiovascular disease in hemodialysis patients. <i>Kidney International</i> , 2008, 73, 1174-1180.	5.2	276
186	Surgical Treatment of Persistent Hyperparathyroidism After Renal Transplantation. <i>Annals of Surgery</i> , 2008, 248, 18-30.	4.2	105
187	Control of hyperphosphatemia beyond phosphate. <i>Kidney International</i> , 2007, 71, 376-379.	5.2	12
188	Parathyroidectomy after successful kidney transplantation: a single centre study. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 1730-1737.	0.7	96
189	Response to "Superior dialytic clearance of $\beta_2$ -microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis". <i>Kidney International</i> , 2007, 71, 467-468.	5.2	1
190	Recurrence of light chain deposit disease after renal allograft transplantation: potential role of rituximab?. <i>Transplant International</i> , 2007, 20, 381-385.	1.6	24
191	Another devastating complication of the Schnitzler syndrome: AA amyloidosis. <i>British Journal of Dermatology</i> , 2007, 158, 071018053044006-???	1.5	29
192	Tertiary "Hyperphosphatemia" Accentuates Hypophosphatemia and Suppresses Calcitriol Levels in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2007, 7, 1193-1200.	4.7	143
193	Major Coagulation Disturbances During Fractionated Plasma Separation and Adsorption. <i>American Journal of Transplantation</i> , 2007, 7, 2195-2199.	4.7	65
194	Heparin-Coated Polyacrylonitrile Membrane Versus Regional Citrate Anticoagulation: A Prospective Randomized Study of 2 Anticoagulation Strategies in Patients at Risk of Bleeding. <i>American Journal of Kidney Diseases</i> , 2007, 49, 642-649.	1.9	68
195	Late Referral of Patients With Chronic Kidney Disease: No Time to Waste. <i>Mayo Clinic Proceedings</i> , 2006, 81, 1487-1494.	3.0	50
196	Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. <i>Critical Care</i> , 2006, 10, R108.	5.8	221
197	The influence of inulin on the absorption of nitrogen and the production of metabolites of protein fermentation in the colon. <i>British Journal of Nutrition</i> , 2006, 96, 1078-1086.	2.3	53
198	Clinically Relevant Drug Interaction Between Voriconazole and Tacrolimus in a Primary Renal Allograft Recipient. <i>Transplantation</i> , 2006, 81, 1750-1752.	1.0	21

#	ARTICLE	IF	CITATIONS
199	Prometheus Versus Molecular Adsorbents Recirculating System: Comparison of Efficiency in Two Different Liver Detoxification Devices. <i>Artificial Organs</i> , 2006, 30, 276-284.	1.9	105
200	Review article: non-biological liver support in liver failure. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 351-363.	3.7	59
201	Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. <i>Kidney International</i> , 2006, 69, 1081-1087.	5.2	340
202	Acarbose treatment lowers generation and serum concentrations of the protein-bound solute p-cresol: A pilot study. <i>Kidney International</i> , 2006, 70, 192-198.	5.2	63
203	p-Cresol for better or worse: But what are we measuring?. <i>Kidney International</i> , 2006, 70, 232.	5.2	7
204	Superior dialytic clearance of $\beta_2$ -microglobulin and p-cresol by high-flux hemodialysis as compared to peritoneal dialysis. <i>Kidney International</i> , 2006, 70, 794-799.	5.2	93
205	Protein-losing enteropathy in association with constrictive pericarditis. <i>International Journal of Cardiovascular Imaging</i> , 2006, 22, 389-392.	1.5	14
206	Drug Interaction Between Itraconazole and Sirolimus in a Primary Renal Allograft Recipient. <i>Transplantation</i> , 2005, 79, 737.	1.0	21
207	Secondary effects of immunosuppressive drugs after simultaneous pancreas-kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, ii33-ii39.	0.7	18
208	Genetic and clinical factors influence the baseline permeability of the peritoneal membrane. <i>Kidney International</i> , 2005, 67, 2477-2487.	5.2	108
209	In vivo evaluation of a colonic delivery system using isotope techniques. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 187-194.	3.7	16
210	Acute-onset, steroid-sensitive, encapsulating peritoneal sclerosis in a renal transplant recipient. <i>American Journal of Kidney Diseases</i> , 2005, 45, e33-e37.	1.9	30
211	Time Profiles of Peritoneal and Renal Clearances of Different Uremic Solutes in Incident Peritoneal Dialysis Patients. <i>American Journal of Kidney Diseases</i> , 2005, 46, 512-519.	1.9	77
212	Adjuvant Low-Dose Cidofovir Therapy for BK Polyomavirus Interstitial Nephritis in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2005, 5, 1997-2004.	4.7	157
213	The molecular adsorbent recycling system (MARS) and transmembrane transport of albumin-bound toxins. <i>Liver Transplantation</i> , 2005, 11, 853-854.	2.4	10
214	Validation of lactose-[15N,15N]ureide as a tool to study colonic nitrogen metabolism. <i>American Journal of Physiology - Renal Physiology</i> , 2005, 288, G994-G999.	3.4	20
215	Gas Chromatographic-Mass Spectrometric Analysis for Measurement of p-Cresol and Its Conjugated Metabolites in Uremic and Normal Serum. <i>Clinical Chemistry</i> , 2005, 51, 1535-1538.	3.2	172
216	A simplified strategy for clinical management of late cytomegalovirus infection after oral ganciclovir prophylaxis in renal recipients. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 55, 391-394.	3.0	8

#	ARTICLE	IF	CITATIONS
217	Detoxifying Capacity and Kinetics of Prometheus <sup>®</sup> : A New Extracorporeal System for the Treatment of Liver Failure. <i>Blood Purification</i> , 2005, 23, 349-358.	1.8	82
218	A Prospective, Randomized, Double-Blind Crossover Study on the Use of 5% Citrate Lock versus 10% Citrate Lock in Permanent Hemodialysis Catheters. <i>Blood Purification</i> , 2005, 23, 101-105.	1.8	27
219	Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1714-1720.	0.7	123
220	Immunosuppressive Drugs After Simultaneous Pancreas-Kidney Transplantation. <i>Transplantation Proceedings</i> , 2005, 37, 2840-2842.	0.6	10
221	Heparin-Coated Hemodialyzers –The Holy Grail for Patients at Risk of Bleeding?. <i>Nephron Clinical Practice</i> , 2004, 97, c1-c2.	2.3	1
222	Nephrogenic fibrosing dermopathy: a novel, disabling disorder in patients with renal failure. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 469-473.	0.7	69
223	Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1281-1287.	0.7	273
224	A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 1895-1901.	0.7	83
225	The value of tuberculin skin testing in haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 433-438.	0.7	54
226	Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. <i>Kidney International</i> , 2004, 65, 1842-1849.	5.2	206
227	Removal of the protein-bound solute p-cresol by convective transport: A randomized crossover study. <i>American Journal of Kidney Diseases</i> , 2004, 44, 278-285.	1.9	155
228	Acute toxic renal failure. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2004, 18, 37-52.	4.0	52
229	THE RATE OF GASTRIC EMPTYING DETERMINES THE TIMING BUT NOT THE EXTENT OF ORAL TACROLIMUS ABSORPTION: SIMULTANEOUS MEASUREMENT OF DRUG EXPOSURE AND GASTRIC EMPTYING BY CARBON-14-OCTANOIC ACID BREATH TEST IN STABLE RENAL ALLOGRAFT RECIPIENTS. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1421-1425.	3.3	28
230	Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 434-447.	4.7	157
231	Time-Related Clinical Determinants of Long-Term Tacrolimus Pharmacokinetics in Combination Therapy with Mycophenolic Acid and Corticosteroids. <i>Clinical Pharmacokinetics</i> , 2004, 43, 741-762.	3.5	102
232	Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis. <i>New England Journal of Medicine</i> , 2004, 350, 1516-1525.	27.0	1,023
233	189 Improvement in systemic hemodynamics after mars is associated with a decrease in vasoactive substances in patients with acute on chronic liver failure (AOCLF): Results of a randomised trial. <i>Journal of Hepatology</i> , 2004, 40, 61-62.	3.7	1
234	Validation of a New Test Meal for a Protein Digestion Breath Test in Humans. <i>Journal of Nutrition</i> , 2004, 134, 806-810.	2.9	21

#	ARTICLE	IF	CITATIONS
235	Influence of SDZ RAD vs. MMF on gastric emptying in renal transplant recipients. <i>Clinical Transplantation</i> , 2003, 17, 171-176.	1.6	12
236	The use of an anti-CD25 monoclonal antibody and mycophenolate mofetil enables the use of a low-dose tacrolimus and early withdrawal of steroids in renal transplant recipients. <i>Clinical Transplantation</i> , 2003, 17, 234-241.	1.6	54
237	Removal of middle molecules and protein-bound solutes by peritoneal dialysis and relation with uremic symptoms. <i>Kidney International</i> , 2003, 64, 2238-2243.	5.2	178
238	Evidence for impaired assimilation of protein in chronic renal failure. <i>Kidney International</i> , 2003, 64, 2196-2203.	5.2	107
239	Kidney transplantation with rabbit antithymocyte globulin and sirolimus monotherapy. <i>Lancet</i> , The, 2003, 361, 969.	13.7	0
240	Long-Term Changes in Mycophenolic Acid Exposure in Combination with Tacrolimus and Corticosteroids Are Dose Dependent and Not Reflected by Trough Plasma Concentration: A Prospective Study in 100 De Novo Renal Allograft Recipients. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 866-880.	2.0	99
241	A young patient with unexplained acute hepatorenal dysfunction. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 1220-1222.	0.7	4
242	<sup>13</sup> C-breath tests in peritoneal dialysis patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2003, 15, 931-932.	1.6	3
243	Long-Term Pharmacokinetic Study of the Novel Combination of Tacrolimus and Sirolimus in De Novo Renal Allograft Recipients. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 447-451.	2.0	20
244	Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. <i>Transplantation</i> , 2003, 75, 665-672.	1.0	142
245	C3D DEPOSITION IN PERITUBULAR CAPILLARIES INDICATES A VARIANT OF ACUTE RENAL ALLOGRAFT REJECTION CHARACTERIZED BY A WORSE CLINICAL OUTCOME. <i>Transplantation</i> , 2003, 76, 102-108.	1.0	47
246	Detoxifying Capacity and Kinetics of the Molecular Adsorbent Recycling System. <i>Blood Purification</i> , 2003, 21, 244-252.	1.8	44
247	A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 923-926.	0.7	38
248	Protective Effect of Parvalbumin on Excitotoxic Motor Neuron Death. <i>Experimental Neurology</i> , 2002, 174, 150-161.	4.1	106
249	role of immunosuppressive drugs in the development of tissue-invasive cytomegalovirus infection in renal transplant recipients. <i>Transplantation Proceedings</i> , 2002, 34, 1164-1170.	0.6	18
250	Activity related increase of exhaled nitric oxide in Crohn's disease and ulcerative colitis: a manifestation of systemic involvement?. <i>Respiratory Medicine</i> , 2002, 96, 530-535.	2.9	41
251	Differential Effect of Diarrhea on FK506 Versus Cyclosporine A Trough Levels and Resultant Prevention of Allograft Rejection in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2002, 2, 989-992.	4.7	58
252	Regional citrate anticoagulation for hemodialysis using a conventional calcium-containing dialysate. <i>American Journal of Kidney Diseases</i> , 2002, 39, 315-323.	1.9	60



#	ARTICLE	IF	CITATIONS
253	An uncommon tumor in a renal graft recipient: A diagnostic and therapeutic challenge. <i>American Journal of Kidney Diseases</i> , 2002, 40, e21.1-e21.6.	1.9	1
254	Early development of megarectum in myotonic dystrophy. <i>Clinical Genetics</i> , 2002, 61, 391-392.	2.0	1
255	The Molecular Adsorbent Recirculating System in patients with severe liver failure: clinical results at the K.U. Leuven. <i>Liver</i> , 2002, 22, 52-55.	0.1	19
256	Magnesium chloride slows gastric emptying, but does not affect digestive functions. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1571-1577.	3.7	6
257	â€˜Full houseâ€™ positive immunohistochemical membranoproliferative glomerulonephritis in a patient with portosystemic shunt. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 2258-2262.	0.7	25
258	Alteration in digestion and absorption of nutrients during profound acid suppression. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2001, 15, 539-551.	2.4	26
259	THE EFFECT OF MYCOPHENOLATE MOFETIL ON HEPATITIS B VIRAL LOAD IN STABLE RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS B. <i>Transplantation</i> , 2001, 72, 1165-1166.	1.0	15
260	POSTTRANSPLANTATION DIABETES MELLITUS IN FK-506-TREATED RENAL TRANSPLANT RECIPIENTS: ANALYSIS OF INCIDENCE AND RISK FACTORS. <i>Transplantation</i> , 2001, 72, 1655-1661.	1.0	128
261	Dialysis Techniques in the Critic Ally-III Patient. <i>Acta Clinica Belgica</i> , 2000, 55, 237-243.	1.2	0
262	<sup>13</sup> C-egg white breath test: a non-invasive test of pancreatic trypsin activity in the small intestine. <i>Gut</i> , 2000, 46, 52-57.	12.1	27
263	Gastric emptying in hyperemesis gravidarum and non-dyspeptic pregnancy. <i>Alimentary Pharmacology and Therapeutics</i> , 1999, 13, 237-243.	3.7	88
264	Determination of Deuterated Phenylalanine and Tyrosine in Egg Protein by GCQ. <i>Journal of High Resolution Chromatography</i> , 1999, 22, 465-468.	1.4	2
265	Evidence for impaired assimilation and increased colonic fermentation of protein, related to gastric acid suppression therapy. <i>Alimentary Pharmacology and Therapeutics</i> , 1998, 12, 1011-1019.	3.7	74
266	Colonic fate of malabsorbed egg protein. <i>Gastroenterology</i> , 1998, 114, A878.	1.3	0
267	Activity related increase of breath nitric oxide in Crohn's disease and ulcerative colitis: A manifestation of systemic involvement. <i>Gastroenterology</i> , 1998, 114, A1011.	1.3	0
268	Direct demonstration of the effect of lactulose on colonic bacterial metabolism by application of lactose-( <sup>15</sup> N)-ureide. <i>Gastroenterology</i> , 1998, 114, A1246.	1.3	1
269	Are protein fermentation metabolites involved in the pathogenesis of ulcerative colitis?. <i>Gastroenterology</i> , 1998, 114, A973.	1.3	0
270	Digestibility of Cooked and Raw Egg Protein in Humans as Assessed by Stable Isotope Techniques. <i>Journal of Nutrition</i> , 1998, 128, 1716-1722.	2.9	116



#	ARTICLE	IF	CITATIONS
271	Influence of dietary protein supplements on the formation of bacterial metabolites in the colon.. Gut, 1997, 41, 70-76.	12.1	200
272	Evaluation of the role of gastric digestion in overall protein assimilation by a combined <sup>13</sup> C-egg white- <sup>14</sup> C-octanoic acid breath test. European Journal of Nutrition, 1997, 36, 374-374.	4.6	0
273	A separation model for breath test analysis. Gastroenterology, 1995, 108, A643.	1.3	0